Vivo Capital
$1.1B 13F equity value
54 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Vivo Capital covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| TRVI | Trevi Therapeutics Inc | 5,094,668 | $95M | 8.7% |
| PRAX | Praxis Precision Medicines | 271,116 | $91M | 8.3% |
| ERAS | Erasca Inc | 4,127,412 | $76M | 6.9% |
| AVBP | Arrivent BioPharma Inc | 1,682,097 | $58M | 5.3% |
| ABVX | Abivax SA - ADR | 414,899 | $55M | 5.0% |
| TNGX | Tango Therapeutics Inc | 1,379,769 | $43M | 3.9% |
| CRVS | Corvus Pharmaceuticals Inc | 2,805,816 | $42M | 3.8% |
| DRUG | Bright Minds Biosciences Inc | 557,172 | $39M | 3.6% |
| SVA | Sinovac Biotech Ltd. | 5,903,000 | $38M | 3.5% |
| TENX | Tenax Therapeutics Inc | 2,500,000 | $36M | 3.3% |
Track Vivo Capital's 13F portfolio: $1.1B in reported holdings, 54 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}